(S)-3-氨基-3-(3-氟苯基)丙酸 | 723284-79-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-3-氨基-3-(3-氟苯基)丙酸
• 中文别名: (S)-3-氨基-3-(3-氟苯基)-丙酸
• 英文名称: (S)-3-amino-3-(3'-fluorophenyl)propanoic acid
• 英文别名: (S)-3-amino-3-(3-fluorophenyl)propanoic acid；(3S)-3-azaniumyl-3-(3-fluorophenyl)propanoate
• CAS: 723284-79-5
• 化学式: C₉H₁₀FNO₂
• mdl: MFCD00764457
• 分子量: 183.182
• InChiKey: GZNJUJNKZBHINS-QMMMGPOBSA-N

物化性质

• 熔点：
  226-229 °C(Solv: water (7732-18-5); acetone (67-64-1))
• 沸点：
  305.7±32.0 °C(Predicted)
• 密度：
  1.289±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
(S)-3-Amino-3-(3-fluoro-phenyl)-propionic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
(S)-3-Amino-3-(3-fluoro-phenyl)-propionic acid
Ingredient name:
CAS number: 723284-79-5

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H10FNO2
Molecular weight: 183.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-3-氨基-3-(3-氟苯基)丙酸 在 盐酸 、 氯化铵 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 36.0h， 生成 (S)-N-(3-amino-1-(3-fluorophenyl)-3-oxopropyl)-3-phenyl-1H-pyrazole-4-carboxamide
  参考文献：
  名称：

  纳摩尔 DCAF1 小分子配体的发现

  摘要：

  DCAF1 是两种不同 E3 连接酶（CRL4 DCAF1和 EDVP）的底物受体，在蛋白质降解中发挥着关键的生理作用，被认为是多种癌症的药物靶点。 DCAF1 拮抗剂可用于开发癌症和病毒治疗疗法。我们使用 DCAF1 的 WDR 结构域筛选包含 1140 亿个化合物的 DNA 编码库 (DEL)，并使用相似性搜索和机器学习识别候选化合物。由此发现了一种 SPR KD为11 μM 的化合物 (Z1391232269)。结构引导的命中优化导致 OICR-8268 ( 26e ) 的发现，通过细胞热位移测定 (CETSA) 测量，其 SPR K D为 38 nM，细胞靶标结合 EC 50为 10 μM。 OICR-8268 是一种出色的工具化合物，可用于开发用于癌症治疗的下一代 DCAF1 配体、进一步研究 DCAF1 在细胞中的功能以及开发基于 DCAF1 的 PROTAC。

  DOI：

  10.1021/acs.jmedchem.2c02132
• 作为产物：
  描述：

  tert-butyl (3S,αR)-3-[N-benzyl-N-(α-methylbenzyl)amino]-3-(3'-fluorophenyl)propanoate 在 盐酸 、 Pd(OH)2/C (6% w/w) 、 水 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、506.66 kPa 条件下， 反应 30.0h， 生成 (S)-3-氨基-3-(3-氟苯基)丙酸
  参考文献：
  名称：

  Asymmetric synthesis of β-fluoroaryl-β-amino acids

  摘要：

  The conjugate addition of lithium (R)-N-benzyl-N-(alpha-methylbenzyl)amide to a range of beta-fluoroaryl-alpha,beta-unsaturated esters gave the corresponding beta-amino esters with high diastereoselectivity and in good isolated yields. Sequential treatment of the resultant beta-fluoroaryl-beta-amino esters under optimised hydrogenolysis conditions, followed by ester hydrolysis with 2.0 M aq HCl, provided access to a range of beta-fluoroaryl-beta-amino acids in good yield. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2012.07.001

文献信息

• Influence of the aromatic moiety in α- and β-arylalanines on their biotransformation with phenylalanine 2,3-aminomutase from Pantoea agglomerans
  作者：Andrea Varga、Gergely Bánóczi、Botond Nagy、László Csaba Bencze、Monica Ioana Toşa、Ákos Gellért、Florin Dan Irimie、János Rétey、László Poppe、Csaba Paizs

  DOI：10.1039/c6ra02964g

  日期：——

  isomerization of various racemic α- and β-arylalanines catalysed by phenylalanine 2,3-aminomutase from Pantoea agglomerans (PaPAM) was investigated. Both α- and β-arylalanines were accepted as substrates when the aryl moiety was relatively small, like phenyl, 2-, 3-, 4-fluorophenyl or thiophen-2-yl. While 2-substituted α-phenylalanines bearing bulky electron withdrawing substituents did not react, the corresponding

  在这项研究中，Pantoea agloglomerans的苯丙氨酸2，3-氨基变位酶催化的各种外消旋α-和β-芳基丙氨酸的对映异构体选择性异构化（PaPAM）进行了调查。当芳基部分相对较小时，如苯基，2-，3-，4-氟苯基或噻吩-2-基，α-和β-芳基丙氨酸均被接受为底物。尽管带有大量吸电子取代基的2-取代的α-苯丙氨酸没有反应，但相应的取代的β-芳基类似物却被迅速转化。3-和4-取代的α-芳基丙氨酸的转化顺利进行，而相应的β-芳基丙氨酸的转化不良或不存在。在pH 7-9范围内，对外消旋α-或β-（噻吩-2-基）丙氨酸的转化率没有明显影响，而氨的浓度（碳酸铵从50 mM增加到1000 mM）则抑制了异构化逐步减少副产物的量（即（E检测到）-3-（噻吩-2-基）丙烯酸。在所有情况下，产物的高ee值表明优异的对映异构体选择性和异构化的立体特异性，除了来自β-异构体的（S）-2-硝基-α-苯丙氨酸（ee
• Kinetic Resolution of Aromatic β-Amino Acids Using a Combination of Phenylalanine Ammonia Lyase and Aminomutase Biocatalysts
  作者：Nicholas J. Weise、Syed T. Ahmed、Fabio Parmeggiani、Nicholas J. Turner

  DOI：10.1002/adsc.201600894

  日期：2017.5.2

  linked to the first ever proposed biosynthesis of pyloricidin‐like secondary metabolites and was shown to display better β‐lyase activity in many cases. In spite of this, a method combining the higher conversion of EncP with a strict α‐lyase from Anabaena variabilis (AvPAL) was found to be more amenable, allowing kinetic resolution of five racemic substrates and a preparative‐scale reaction with >98% (R)

  已经证明了使用苯丙氨酸氨基变位酶和氨裂合酶（PAM和PAL）酶制备（R）-β-芳基丙氨酸的酶促策略。具有海马链霉菌（EncP）和芽孢杆菌（Bacillus sp。）选择性（S）选择性的候选PAM 。（PabH）通过使用充分研究的模板序列进行序列分析来鉴定。新发现的PabH可能与首次提出的幽门螺杆菌样二级代谢产物的生物合成有关，并在许多情况下显示出更好的β-裂合酶活性。尽管如此，ENCP的较高的转化率具有严格α -裂解酶合成的方法从多变鱼腥藻（AvPAL）被认为是更合适的，它允许五种外消旋底物的动力学拆分以及制备规模的对映体过量> 98％（R）的反应。这项工作代表了对现有生物催化策略的一种改进和对映体互补的方法，它允许简单的产品分离和模块化的伸缩组合，以及使用非手性醛作为原料的先前化学步骤。
• The Bacterial Ammonia Lyase EncP: A Tunable Biocatalyst for the Synthesis of Unnatural Amino Acids
  作者：Nicholas J. Weise、Fabio Parmeggiani、Syed T. Ahmed、Nicholas J. Turner

  DOI：10.1021/jacs.5b07326

  日期：2015.10.14

  deracemization cascades (giving (S)- or (R)-α-phenylalanine derivatives, respectively), and also eukaryotic phenylalanine aminomutases (PAMs) for the synthesis of the (R)-β-products. Herein, we present the investigation of another family member, EncP from Streptomyces maritimus, thereby expanding the biocatalytic toolbox and enabling the production of the missing (S)-β-isomer. EncP was found to convert

  I类裂解酶家族的酶催化氨向丙烯酸芳基酯的不对称加成，产生作为产物的高价值氨基酸。最近的例子包括使用苯丙氨酸氨裂解酶 (PAL)，单独使用或作为去消旋级联的途径（分别提供 (S)- 或 (R)-α-苯丙氨酸衍生物），以及真核苯丙氨酸氨基变位酶 (PAM) (R)-β-产物的合成。在此，我们介绍了对来自 Streptomyces maritimus 的另一个家族成员 EncP 的研究，从而扩展了生物催化工具箱并能够生产缺失的 (S)-β-异构体。发现 EncP 将一系列芳基丙烯酸酯转化为 (S)-α- 和 (S)-β-芳基丙氨酸的混合物，其区域选择性与每个底物环上的吸电子/供电子基团的强度相关。野生型酶的低区域选择性通过基于结构的合理设计得到解决，以产生三种对α-或β-产物具有改变偏好的变体。通过检查各种生物催化剂/底物组合，证明可以调整反应的胺化模式，以根据需要实现 99:1 和 1:99 之间的
• Tropane derivatives useful in therapy
  申请人：Pfizer Inc.

  公开号：US20040014742A1

  公开（公告）日：2004-01-22

  The present invention provides compounds of formula (I) 1 wherein X, Y, R 1 , R 2 and R 3 are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of various inflammatory diseases and conditions, and in the treatment of infection by HIV and genetically related retroviruses.

  本发明提供了式(I)中的化合物，其中X、Y、R1、R2和R3如上文所定义。本发明的化合物是化学趋化因子CCR5受体的调节剂，特别是拮抗剂。CCR5受体的调节剂可能在治疗各种炎症性疾病和症状以及治疗HIV和遗传相关逆转录病毒感染方面有用。
• An efficient new enzymatic method for the preparation of β-aryl-β-amino acid enantiomers
  作者：Gábor Tasnádi、Enikő Forró、Ferenc Fülöp

  DOI：10.1016/j.tetasy.2008.08.009

  日期：2008.9

  An efficient synthesis of β-aryl-β-amino acid enantiomers has been developed via the lipase-catalysed enantioselective hydrolysis of the corresponding racemic ethyl esters in an organic solvent. High enantioselectivities (E >100) were observed when the lipase PS-catalysed reactions were performed with H2O (0.5 equiv) in diisopropyl ether at 45 °C. The products could be easily separated and were obtained

  通过在有机溶剂中通过脂肪酶催化的相应外消旋乙酯的对映选择性水解，已经开发了β-芳基-β-氨基酸对映体的有效合成。当脂肪酶PS催化的H 2 O（0.5当量）在二异丙醚中于45°C进行时，观察到高对映选择性（E > 100）。产物易于分离，收率⩾40％。